Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 1233-1238

  Wang, Ying ^a   Wang, Leqiu ^a   Yin, Changhao ^a   An, Baizhu ^a   Hao, Yankun ^a   Wei, Tao ^a   Li, Li ^a   Song, Gaochen ^a  

^a MUDANJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Human ether go go related gene; MCF 7; MicroRNA 328

Indexed keywords

ARSENIC TRIOXIDE; MICRORNA; MICRORNA 328; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; ERG1 POTASSIUM CHANNEL; LUCIFERASE; MIRN328 MICRORNA, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEK293 CELL LINE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ADENOCARCINOMA; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BINDING SITE; BREAST NEOPLASMS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; REPORTER GENE; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BINDING SITES; BREAST NEOPLASMS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEK293 CELLS; HUMANS; LUCIFERASES; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; OXIDES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926627892     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3558     Document Type: Article

References (37)

1. Klaassen CD: Heavy metals and heavy-metal antagonists. In: The Pharmacological Basis of Therapeutics. Gilman (ed.). McGraw-Hill, New York, NY, pp 649-1672, 1996.
2. Cyranoski D: Arsenic patent keeps drug for rare cancer out of reach of many. Nat Med 13: 1005, 2007.
3. Sun HD, Ma L and Hu XC and Zhang TD: Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin W Med 12: 170-171, 1992.
4. Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 35: 1258-1263, 1999.
5. Shen ZY, Shen J, Cai WJ, Hong C and Zheng MH: The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 5: 155-158, 2000.
6. Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455: 59-62, 1999.
7. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6: 4957-4964, 2000.
8. Chow SK, Chan JY and Fung KP: Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem 93: 173-187, 2004.
9. Ye J, Li A, Liu Q, Wang X and Zhou J: Inhibition of mitogen-activated protein kinase kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells. Clin Exp Pharmacol Physiol 32: 1042-1048, 2005.
10. Crociani O, Guasti L, Balzi M, et al: Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J Biol Chem 278: 2947-2955, 2003.
11. Guasti L, Crociani O, Redaelli E, Pillozzi S, PolVani S, Masselli M, Mello T, Galli A, Amedei A, Wymore RS, et al: Identification of a posttranslational mechanism for the regulation of hERG1 K+ channel expression and hERG1 current density in tumor cells. Mol Cell Biol 28: 5043-5060, 2008.
12. Arcangeli A: Expression and role of hERG channels in cancer cells. Novartis Found Symp 266: 225-232, 2005.
13. Wang Y, Zhang Y, Yang L, Cai B, Li J, Zhou Y, Yin L, Yang L, Yang BF and Lu YJ: Arsenic trioxide induces the apoptosis of human breast cancer MCF-7 cells through activation of caspase-3 and inhibition of HERG channels. Exp Ther Med 2: 481-486, 2011.
14. Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, Zhou H and Zhao RC: miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 34: 1461-1466, 2009.
15. Kato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB and Slack FJ: The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 28: 2419-2424, 2009.
16. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601, 2008.
17. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046, 2009.
18. Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R, Lau J, Chen PL and Lee WH: Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res 68: 8393-8399, 2008.
19. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, et al: The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486-491, 2007.
20. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, Zhang Y, Shan H, Luo X, Bai Y, et al: MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 122: 2378-2387, 2010.
21. Shan H, Zhang Y, Lu Y, Zhang Y, Pan Z, Cai B, Wang N, Li X, Feng T, Hong Y, et al: Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 83: 465-472, 2009.
22. Cai B, Pan Z and Lu Y: The roles of microRNAs in heart diseases: A novel important regulator. Curr Med Chem 17: 407-411, 2010.
23. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin: Feb 4, 2015 (Epub ahead of print).
24. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, et al: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27: 2954-2961, 2009.
25. Li H, Liu L, Guo L, et al: HERG K+ channel expression in CD34+/CD38-/CD123(high) cells and primary leukemia cells and analysis of its regulation in leukemia cells. Int J Hematol 87: 387-392, 2008.
26. Afrasiabi E, Hietamäki M, Viitanen T, Sukumaran P, Bergelin N and Törnquist K: Expression and significance of HERG (KCNH2) potassium channels in the regulation of MDA-MB-435S melanoma cell proliferation and migration. Cell Signal 22: 57-64, 2010.
27. Zhao J, Wei XL, Jia YS and Zheng JQ: Silencing of herg gene by shRNA inhibits SH-SY5Y cell growth in vitro and in vivo. Eur J Pharmacol 579: 50-57, 2008.
28. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
29. Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, Zhou H and Zhao RC: miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 34: 1461-1466, 2009.
30. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 285: 17869-17879, 2010.
31. Song B, Wang C, Liu J, Wang X, Lv L, Wei L, Xie L, Zheng Y and Song X: MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 29: 29, 2010.
32. Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ and Schmittgen TD: Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA 14: 35-42, 2008.
33. Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W and Yang Z: MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS One 7: e47270, 2012.
34. Shah MY, Pan X, Fix LN, Farwell MA and Zhang B: 5-Fluorouracil drug alters the microRNA expression profiles in MCF-7 breast cancer cells. J Cell Physiol 226: 1868-1878, 2011.
35. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, et al: miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140: 652-665, 2010.
36. Pan YZ, Morris ME and Yu AM: MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 75: 1374-1379, 2009.
37. Paduano F, Dattilo V, Narciso D, Bilotta A, Gaudio E, Menniti M, Agosti V, Palmieri C, Perrotti N, Fusco A, et al: Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328. FEBS J 280: 401-412, 2013.